The dual-targeting of TRPM4 in combination with any of its interaction partner proteins or tumor-specific membrane proteins with bispecific-antibodies carrying toxins could diminish the risk of unwanted side effects in other tissues of the body. Here, TRPM4 is linked to neoplasm.